Document:

Exhibit
10.1

 

 

July
31, 2022

 

Ryan
Melsert

Via
E-Mail: rmelsert@batterymetals.com

 

Dear
Mr. Melsert,

 

On
behalf of American Battery Technology Company (the “Company”), I am pleased to outline in this letter (the “Offer
Letter” or “Agreement”) the terms and conditions on which we are extending your positions of Chief Executive
Officer (CEO) and Chief Technology Officer (CTO) (jointly referred to herein as “CEO”) of the Company. This
Offer Letter will not constitute an agreement until it has been fully executed by both parties.

 

1.
Position and Duties.

 

1.1
Position. Subject to the terms and conditions hereof, this contract becomes effective as of August 1, 2022 (the “Employment
Date”).

 

1.2
Responsibilities.

 

(a)
As the Company’s CEO, you will report to the Company’s Board of Directors and have such duties and responsibilities as may
be assigned to you from time to time.

 

(b)
You agree to devote all your business time and attention to the business and affairs of the Company and to fulfill the responsibilities
assigned to you. This shall not preclude you from (i) serving on the boards of directors of a reasonable number of charitable organizations,
(ii) engaging in charitable activities and community affairs, and (iii) managing your personal affairs, so long as these activities do
not interfere with the performance of your duties and responsibilities as the CEO. During the term of your employment, you agree to adhere
to and follow all written internal rules and regulations governing the conduct of the Company’s employees as established or modified
from time to time, provided, however, that in the event of any conflict between the provisions of this Offer Letter and any such rules
or regulations, the provisions of this Offer Letter shall control. You acknowledge that the Company is a public company and you agree
that you are required to adhere to the Company’s policies related thereto.

 

1.3
Exclusive Services. During your employment by the Company, you shall not, without the express prior written consent of the
Company, engage directly or indirectly in any outside employment or consulting of any kind, irrespective of whether you receive remuneration
for such services, or other activity that relates to any line of business in which the Company or any of its Affiliates (as defined in
Exhibit A) are at that time engaged or plan to engage in, or that may, now or in the future, otherwise conflict with your
employment obligations, contractual duties, or fiduciary obligations to the Company, provided, however, that nothing in this Agreement
shall prevent you from owning, in the aggregate, five percent (5%) or less of the outstanding equity interests of a company whose securities
are traded on a national security exchange or on an over-the-counter market.

 

    	 

    	 

    

 

1.4
No Employment Restriction. You hereby represent and covenant that, except as disclosed to the Company, your employment by
the Company does not violate any agreement or covenant to which you are subject or by which you are bound and that there is no such agreement
or covenant that could restrict or impair your ability to perform your duties or discharge your responsibilities to the Company.

 

1.5
Location. Your place of work will be Reno, Nevada, in the Company’s main offices.

 

2.
Compensation.

 

2.1
Base Salary. Your annual base salary will initially be as set forth on the attached Schedule A (“Annual Base
Salary”) and paid according to the Company’s regular payroll practice throughout the calendar year, pro-rated for any
partial periods based on the actual number of days in the applicable period. Your performance will be evaluated at least annually and
any increase to the level of your Annual Base Salary will be determined as part of the regular annual review process.

 

2.2
Bonus. All annual bonuses to which you are entitled, if any, shall be listed on the attached Schedule A and
updated annually. Unless stated explicitly otherwise, all bonuses shall only be as approved by the Board of Directors of the Company
in its sole and absolute discretion.

 

2.3
Equity Compensation. All equity compensation to which you are entitled, if any, shall be listed on the attached Schedule
A.

 

3.
Benefits.

 

3.1
Benefit Program. Effective as of the Employment Date, you will be eligible to participate in the Company’s benefit programs
available to other employees of the Company at your level.

 

3.2
Unlimited Time-Off Policy. The system is known as “unlimited time-off policy” or “unlimited paid time off.”
It is a vacation policy that allows employees to take as much free time as they feel they need as long as it does not interfere with
their work responsibilities, work completion, and the quality of their work. The system is designed to provide the employee flexibility
as a reward for making productive use of work hours. The employee is paid for the time they take off from their job. The employee cannot
take off more than fourteen consecutive calendar days. Paid time off (“PTO”) is not counted or allocated, and is not
accrued, and the employee takes off as much time as needed for vacation, family issues, sick days, etc. Should the employee’s time
off impact their productivity, the employee’s time off will be more closely monitored and compared to the job responsibilities
of that employee. Unlimited paid time off is a reward for job excellence, not an entitlement.

 

    	2

    	 

    

 

3.3
Reimbursement. You will be reimbursed for out-of-pocket expenses reasonably incurred in connection with the performance of
your duties in accordance with the Company’s policies as established from time to time.

 

3.4
No Other Benefits. You will not be entitled to any benefit or perquisite other than as specifically set out in this Offer
Letter or separately agreed to in writing by the Company.

 

4.
Termination; Payments and Entitlements upon Termination

 

4.1
Employment Term. The employment term and your employment hereunder may be terminated by either the Company or by you at any
time and for any reason, provided that, unless otherwise provided herein, you are required to give the Company at least sixty (60) days’
advance written notice of your termination of employment, whether with or without Good Reason (as defined in the attached Exhibit
A). Upon termination of employment during the employment term, you shall be entitled to the compensation and benefits as described
in this Section 4 and shall have no further rights to any compensation or any other benefits from the Company or any of its Affiliates.

 

4.2
Written Notice of New Employer or Enterprise. You further agree that should you find new employment or initiate activity to
form a new business or enterprise at any time within (a) the Initial Noncompete Period (as defined in the attached Exhibit A)
or (b) to the extent the Board of Directors opts to exercise its discretion and request, at any time prior to the expiration of the Initial
Noncompete Period, that an Option Noncompete Period (as defined in the attached Exhibit A) go into effect, you will provide
the Company with written notice of such proposed new employment or initiation of activity to form a new business or enterprise. Such
notice shall include (i) the name of your proposed new employer, business or enterprise, (ii) the position to be assumed by you and (iii)
a detailed description of the nature of the proposed business activities and your intended role at such employer, business or enterprise.
Within fifteen (15) business days from its receipt of such written notice, the Company will evaluate whether such new employment, business
or enterprise by you would violate any of the Restrictive Covenants or any other noncompete restrictions in this Agreement. The Company
agrees to exercise its reasonable judgement in making this determination. If the Company determines that the acceptance by you of such
proposed new employment or initiation of a new business or enterprise would not constitute a potential violation of the Restrictive Covenants
or any other noncompete restrictions in this Agreement, the Company will provide you with a written release (such release, a “New
Employment Release Notice”). Upon the receipt by you of a New Employment Release Notice, you shall be permitted to accept such
new employment or form such new business or enterprise. If the Company determines that your proposed new employment, business or enterprise
would be in violation of the non-competition provisions of this Agreement, the Company will furnish to you, within that same fifteen
(15) business day period, a written notice that sets forth the reasons why a potential or actual violation may exist (such rejection,
a “New Employment Prohibition Notice”). Upon the receipt by you of a New Employment Prohibition Notice, you shall
not be permitted to accept such new employment or initiate such new business or enterprise. Notwithstanding the foregoing, the issuance
of any New Employment Release Notice shall have no impact on your obligation to abide by the Restrictive Covenants and any other noncompete
restrictions in this Agreement, which shall remain in full force in effect until the end of the Initial Noncompete Period and, to the
extent the Board of Directions has exercised its right to put into effect the Option Noncompete Period, the Option Noncompete Period.

 

    	3

    	 

    

 

4.3
Discretionary Salary Continuation; Right to Recoup

 

(a)
Discretionary Salary Continuation. To the extent the Company exercises its right to put into effect an Option Noncompete
Period, and no CIC Severance Payment has been made pursuant to Section 4.6, the Company, after receiving from you an executed irrevocable
release (as described in Section 4.8 below), will pay you on a pro-rated basis the salary you received in your last role with
the Company (“Option Period Payment”). Such salary shall begin to accrue on the later of (i) the first day of the
Option Noncompete Period and (ii) the date of receipt by the Company of your executed irrevocable release (as described in Section 4.8
below). You further acknowledge and agree that the Company may, at any time and in its sole and absolute discretion, choose to waive
its rights under this Agreement and not elect to exercise (or, if applicable, cease) payment of the salary continuation during the Option
Noncompete Period.

 

(b)
End of Salary Continuation. If at any time you find new employment during the Option Noncompete Period, you agree to proceed
in accordance with Section 4.2 to obtain approval from the Company. In the event that such new employment is approved by the Company
as not violating the provisions of this Agreement, you acknowledge and agree that the Company shall immediately discontinue any further
payments during the Option Period as of the date immediately preceding the first day of such new employment (such date, the “End
of Salary Continuation Date”) and the remaining provisions of this Agreement shall remain in full force and effect.

 

(c)
Right to Recoup Payments. As long as the Company chooses to pay you, those payments will be made to you in regular installments
as if you had remained a Company employee. Any amounts that you earn during the Option Period in a position and/or business enterprise
that is not in violation of this Agreement will be subtracted from the payments from the Company to you. You further acknowledge and
agree that in the event that such amounts you earn are not subtracted from the payments received from the Company, you will reimburse
the Company in the amounts equal to what you earned during the Option Period. You further acknowledge and agree that the Company has
the right to pursue all remedies available at law and equity to recoup any payments in the event you fail to reimburse the Company for
such amounts.

 

4.4
Termination by Company for Cause or by Employee without Good Reason. If this Agreement is terminated by the Company for Cause
or by you without Good Reason, you will be entitled to accrued but unpaid salary owed to you through the date of termination, accrued
but unpaid vacation, and reimbursement for any legitimate business expenses, but you shall forfeit any other form of compensation,
including but not limited to cash equity compensation and bonus compensation not already received by you or not already vested as of
the date of termination. Any vested but unexercised options or warrants must be exercised by the earlier of (i) the one-year anniversary
of the date of termination, or (iii) the expiry of such option’s or warrant’s term. You will not be eligible for any
continuing benefits such as health insurance or COBRA coverage. In addition, the Company, in its sole discretion, may require you to
return any already vested equity compensation set forth on the attached Schedule A.

 

    	4

    	 

    

 

4.5
Termination by Company without Cause or by Employee with Good Reason. Subject to Sections 4.3, 5.9, and 7.11, if your employment
is terminated following the date of this Offer Letter (i) by the Company without Cause other than by reason of your Disability (as defined
in the attached Exhibit A) or (ii) by you for Good Reason (either (i) or (ii), an “Involuntary Termination”), you
will be entitled to accrued but unpaid salary owed to you through the date of termination, reimbursement for any legitimate business
expenses, and cash bonus compensation for any milestones that were achieved prior to the date of termination, but you shall forfeit any
other form of compensation, including but not limited to equity compensation not already accrued or vested as of the date of termination.
Any vested but unexercised options or warrants must be exercised by the earlier of (i) the one-year anniversary of the End of Salary
Continuation Date of the Option Period or (ii) the expiry of such option’s or warrant’s term. In addition, you will be entitled
to an additional amount equal to twelve (12) months’ salary (“Severance Payment”) minus all applicable withholding
taxes, which shall be paid in regular installments as if you had remained a Company employee after the Company receives from you an executed
irrevocable release (as described in Section 4.8 below). Finally, the Company will pay for twelve (12) months of COBRA coverage for you.

 

4.6
Involuntary Termination with Change in Control. If an Involuntary Termination occurs within 24 months following a Change in
Control (as that term is defined in the Company’s Equity Incentive Plan or any subsequent plan that replaces that plan), and after
the Company receives from you an executed irrevocable release, you will be entitled to: (a) an amount equal to twelve (12) months’
salary minus all applicable withholding taxes and (b) an amount equal to the amount of cash bonus paid to you under Section 6.5 (together,
the “CIC Severance Payment”). The CIC Severance Payment will be made in addition to the Severance Payment described
in Section 4.5 above. The CIC Severance Payment shall be paid within thirty (30) days after the Company receives from you an executed
irrevocable release (as described in Section 6.8 below). Further, (a) all unvested equity compensation, including but not limited to
options or warrants, shall vest immediately upon you becoming entitled to CIC Severance Payment and (b) the Company will pay for twelve
(12) months of COBRA coverage for you. Any vested but unexercised options or warrants must be exercised by the earlier of (i) the one-year
anniversary of the date of termination or (ii) the expiration of such option’s or warrant’s term.

 

4.7
Termination Due to Death or Disability. In the event your employment is terminated by death or Disability (as defined in the
attached Exhibit A), you or your dependents will be entitled to accrued but unpaid salary owed to you through the date
of termination, reimbursement for any legitimate business expenses, and a cash bonus for any milestones that were achieved prior to the
date of termination, Further, (a) all unvested equity compensation, including but not limited to options, shall vest immediately upon
your termination due to death or Disability, and (b) the Company will pay for twelve (12) months of COBRA coverage for you (if termination
is due to your Disability) or your dependents (if termination is due to your death). Any vested but unexercised options must be exercised
within 90 days of the date of termination.

 

4.8
Release Required. You will be required to execute an irrevocable release in favor of the Company in order to be entitled to
receive any Option Period Payment, Severance Payment, CIC Severance Payment, or benefits described in Section 6 of this Agreement. The
release must be executed within seven days of the date of termination. The release must be in favor of the Company and related parties
relating to all claims or liabilities of any kind regarding your employment with the Company and the Involuntary Termination of such
employment.

 

    	5

    	 

    

 

4.9
Resignation. If you are a director or officer of the Company, or a director or an officer of a company affiliated or related
to the Company at the time of your termination, you will be deemed to have resigned all such positions on the date of your termination,
and you agree that upon termination you will execute such tenders of resignation as may be requested by the Company to evidence such
resignations.

 

4.10
Rights under Equity Plans. The provisions of this Offer Letter are subject to the terms of the Company’s equity plans
in effect from time to time. Any equity awards granted to you under the equity plans will follow the terms of the applicable and current
equity plans of the Company.

 

4.11
Cooperation. From and after termination, you agree, upon the Company’s request, to cooperate in any investigation, litigation,
arbitration, or regulatory proceeding regarding events that occurred during the time of your employment by the Company or its Affiliates.
You will make yourself available to consult with Company’s counsel, to provide information, to appear for testimony and take such
other measures as the Company may reasonably request in respect of your cooperation. The Company will, to the extent permitted by law,
reimburse you for any reasonable out-of-pocket expenses that you incur in extending such cooperation, so long as you provide the Company
with advance written notice of your request for reimbursement and provide satisfactory documentation of such expenses.

 

5.
Restrictive Covenants.

 

5.1
Confidentiality.

 

(a)
You acknowledge that in the course of carrying out, performing, and fulfilling your obligations to the Company hereunder, you will have
access to and will be entrusted with information that would reasonably be considered confidential to the Company or its Affiliates, the
disclosure of which to competitors of the Company, its Affiliates, or to the general public, will be highly detrimental to the best interests
of the Company or its Affiliates. Such information includes, without limitation, trade secrets, know-how, marketing plans and techniques,
cost figures, client lists, software, and information relating to employees, suppliers, customers and persons in contractual relationship
with the Company, technical information, lists of asset sources, the processes and practices of the Company, all information contained
in electronic or computer files, all financial information, salary and wage information, and any other information that is designated
by the Company or its Affiliates as confidential or that you know is confidential, information provided by third parties that the Company
or its Affiliates are obligated to keep confidential, and all other proprietary information of the Company or its Affiliates (“Confidential
Information”). Except as may be required in the course of carrying out your duties hereunder, you covenant and agree that you
will not disclose, for the duration of your employment or at any time thereafter, any such information to any person, other than to the
directors, officers, employees or agents of the Company that have a need to know such information, nor shall you use or exploit, directly
or indirectly, such information for any purpose other than for the purposes of the Company, nor will you disclose or use for any purpose,
other than for those of the Company or its Affiliates, any other information which you may acquire during your employment with respect
to the business and affairs of the Company or its Affiliates. You further covenant and agree for the duration of your employment and
at any time thereafter to exercise the highest degree of care in safeguarding confidential information against loss, theft, or other
inadvertent disclosure and agree generally to take all steps necessary or requested by the Company to ensure maintenance of the confidentiality
of the confidential information. Notwithstanding all the foregoing, you shall be entitled to disclose such information if required pursuant
to a subpoena or order issued by a court, arbitrator, or governmental body, agency or official, provided you shall first have:

 

    	6

    	 

    

 

(i)
notified the Company;

 

(ii)
consulted with the Company on whether there is an obligation or defense to providing some or all the requested information; and

 

(iii)
if the disclosure is required or deemed advisable, cooperate with the Company to obtain an order or other assurance that such information
will be accorded confidential treatment.

 

Your
obligations under this Offer Letter with regard to any particular Confidential Information shall commence immediately upon your first
having access to such Confidential Information (whether before or after you begin employment with the Company) and shall continue during
and after your employment by the Company until such time as such Confidential Information has become public knowledge other than as a
result of your breach of this Offer Letter or breach by those acting in concert with the you or on your behalf.

 

(b)
Notwithstanding the foregoing, you may disclose information relating to your own compensation and benefits to your spouse, attorneys,
financial advisors, and taxing authorities. Please note that pursuant to rules promulgated by the U.S. Securities and Exchange Commission
under the Securities Exchange Act of 1934 in effect as of the date hereof, the amount and components of your compensation may be required
to be publicly disclosed on an annual basis.

 

(c)
Nothing herein prohibits or restricts you (or your attorney) from initiating communications directly with, responding to any inquiry
from, or providing testimony before the Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA),
any other self-regulatory organization, or any other federal or state regulatory authority regarding a securities law violation.

 

    	7

    	 

    

 

5.2
Intellectual Property. You acknowledge and agree that all right, title, and interest in and to any information, trade secrets,
advances, discoveries, improvements, formulae, techniques, processes, research materials, databases, and know-how, whether or not patentable,
and whether or not reduced to practice, that are made, conceived, or developed by you, either alone or jointly with others, if on the
Company’s time, using Company’s facilities, or relating to the business or affairs of the Company, shall belong exclusively
to the Company. You agree that the Company shall be the sole owner of all domestic and foreign patents or other rights pertaining thereto,
and further agree to execute all documents that the Company reasonably determines to be necessary or convenient for use in applying for,
prosecuting, perfecting, or enforcing patents or other intellectual property rights, including the execution of any assignments, patent
applications, or other documents that the Company may reasonably request. Additionally, you agree that all original works of authorship
not otherwise within the scope of the preceding sentence that are conceived or developed during your engagement with the Company, either
alone or jointly with others, if on the Company’s time, using Company’s facilities, or relating to the Company shall be owned
exclusively by the Company. You agree that the Company shall be the sole owner of all rights pertaining thereto, and further agree to
execute all documents that the Company determines to be necessary or convenient for establishing in the Company’s name the copyright
to any such original works of authorship. In connection with the foregoing, you agree to execute any assignments and/or acknowledgements
as may be requested by the Company from time to time. You agree not to claim an interest in any inventions, copyrighted material, patents,
or patent applications unless you demonstrate that any such invention, copyrighted material, patent, or patent application was developed
before you began providing any services for the Company. This provision is intended to apply only to the extent permitted by applicable
law.

 

5.3
Corporate Opportunities. Any business opportunities related to the business of the Company which become known to you during
your employment with the Company must be fully disclosed and made available to the Company by you, and you agree not to take or attempt
to take any action if the result would be to divert from the Company any opportunity which is within the scope of its existing or future
business.

 

5.4
Non-Competition and Non-Solicitation.

 

(a)
Non-Competition. You will not at any time, without the prior written consent of the Company, during (i) your employment
with the Company and (ii)(A) the Initial Noncompete Period and (B) the Option Noncompete Period (in respect of (B), only to the extent
the Board of Directors opts to exercise its discretion and request, at any time prior to the expiration of the Initial Noncompete Period,
that an Option Noncompete Period go into effect), either individually or in partnership, jointly, or in conjunction with any person or
persons, firm, association, syndicate, corporation, or company, whether as agent, shareholder, employee, consultant, or in any manner
whatsoever, directly or indirectly:

 

(i)
anywhere in the Territory (as defined in the attached Exhibit A), engage in, carry on, assist, or otherwise have any interest
in, advise, lend money to, guarantee the debts or obligations of, or permit your name to be used in connection with any business which
is a Competitive Business (as defined below);

 

(ii)
for the purpose, or with the effect, of assisting any Competitive Business (as defined below), solicit, interfere with, accept any business
from, or render any services to anyone who is a client or a prospective client of the Company or any Affiliate at the time you ceased
to be employed by the Company or who was a client during the twelve (12) months immediately preceding such time;

 

(iii)
For purposes of this Section 5.4(a), a “Competitive Business” means a business involved in or pursuing business opportunities
in battery recycling, battery materials processing, lithium extraction, lithium processing, or which otherwise provides similar
services as the Company;

 

(iv)
Nothing in this Offer Letter shall prevent you from owning, in the aggregate, five percent (5%) or less of the outstanding equity interests
of a company whose securities are traded on a national security exchange or on an over-the-counter market.

 

    	8

    	 

    

 

(b)
Non-Solicitation of Employees. You will not at any time, without the prior written consent of the Company, during your
employment with the Company and for a period of time equal to the Initial Noncompete Period and the Option Noncompete Period, as applicable,
one, either individually or in partnership, jointly or in conjunction with any person or persons, firm, association, syndicate, corporation,
or company, whether as agent, shareholder, employee, consultant, or in any manner whatsoever, directly or indirectly, solicit or offer
employment to any person employed or engaged by the Company or any Affiliate at the time you ceased to be employed by the Company or
who was an employee during the 12-month period immediately preceding such time.

 

(c)
Non-Solicitation of Customers. You will not at any time, without the prior written consent of the Company, during your
employment with the Company and for a period of time equal to the Initial Noncompete Period and the Option Noncompete Period, as applicable,
either individually or in partnership, jointly or in conjunction with any person or persons, firm, association, syndicate, corporation
or company, whether as agent, shareholder, employee, consultant, or in any manner whatsoever, directly or indirectly, solicit the business
of or provide services or good similar to the services or goods provided by the Company to any Customer or any other entity with which
the Company has an agreement to perform services or provide goods during the six (6) month period prior to your separation from the Company.
You further agree not to directly or indirectly contact any Customers for the purpose of soliciting such Customer to purchase or license
a product or service that is the same as, similar to or in competition with those products and/or services offered, made or rendered
by the Company.

 

(d)
Non-Solicitation of Suppliers or Service Providers. You will not at any time, without the prior written consent of the
Company, during your employment with the Company and for a period of time equal to the Initial Noncompete Period and the Option Noncompete
Period, as applicable, either individually or in partnership, jointly or in conjunction with any person or persons, firm, association,
syndicate, corporation or company, whether as agent, shareholder, employee, consultant, or in any manner whatsoever, directly or indirectly,
solicit the services or goods to any Supplier or Service Provider or any other entity with which the Company has an agreement to receive
the same or similar goods or services during the six (6) month period prior to your separation from the Company.

 

(e)
If you are, at any time, in violation of any provision of this Section 5.4, then each time limitation set forth in this Section 5.4 shall
be extended for a period equal to the period during which such violation or violations occur. If the Company seeks injunctive relief
from any such violation, then the covenants set forth shall be extended for a period equal to the pendency of the proceeding in which
relief is sought, including all appeals therefrom.

 

    	9

    	 

    

 

5.5
Material Non-Public Information. You acknowledge that information about the Company received by you during the term of your
employment may constitute material, non-public information and you are aware of the restrictions imposed by the United States securities
laws on (a) the purchase or sale of securities by any person who is aware of material, non-public information and (b) on the communication
of such information to any other person who may purchase or sell such securities on the basis of such information (including those persons
who may be permitted to receive such information). You agree that you will comply with all applicable federal and state securities laws
in connection with the purchase or sale, directly or indirectly, of securities of the Company or any other company for which you receive
confidential information in connection with your employment. You further agree to comply in all respects with the Company’s Insider
Trading Policy and Insider Reporting Procedures with respect to any securities of the Company that you may acquire, and you will comply
with all other Company’s policies that may be applicable to you from time to time.

 

5.6
Non-Disparagement. You will not disparage the Company or any of its Affiliates, directors, officers, employees or other representatives
in any manner and you will in all respects avoid any negative criticism of the Company. This Section 5.6 does not, in any way, restrict
or impede you from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any
applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that
such compliance does not exceed that required by the law, regulation, or order. The Company agrees and covenants that it shall direct
its officers and directors to refrain from making any defamatory or disparaging remarks, comments, or statements concerning you to any
third parties.

 

5.7
Injunctive Relief.

 

(a)
You acknowledge and agree that in the event of a breach of the covenants, provisions, and restrictions in this Section 5, the Company’s
remedy in the form of monetary damages will be inadequate and that the Company shall be, and is hereby, authorized and entitled, in addition
to all other rights and remedies available to it, to apply for and obtain from a court of competent jurisdiction interim and permanent
injunctive relief and an accounting of all profits and benefits arising out of such breach.

 

(b)
You acknowledge that the restrictions in this Section 5 are reasonable in all the circumstances, and you acknowledge that the operation
of restrictions contained in this Section 5 may seriously constrain your freedom to seek other remunerative employment. If any
of the restrictions are determined to be unenforceable as going beyond what is reasonable in the circumstances for the protection of
the interests of the Company but would be valid, for example, if the scope of their time periods or geographic areas were limited, you
consent to the court making such modifications as may be required and such restrictions shall apply with such modifications as may be
necessary to make them valid and effective.

 

5.8
Survival of Restrictions. Each provision of this Section 5 shall survive the termination of this Offer Letter or the termination
of your employment (regardless of the reason for such termination).

 

5.9
Forfeiture. Notwithstanding the provisions of Sections 6.3 or 6.5, if, following any Involuntary Termination, it shall be
determined that you have breached (either before or after such termination) any of the agreements in this Section 5, the Company shall
have no obligation or liability or otherwise to make any further payment under Sections 6.3 or 6.5 from and after the date of such breach,
except for payments, if any, that cannot legally be forfeited.

 

    	10

    	 

    

 

6
Code Section 409A Deferred Compensation.

 

6.1
In General. This Section 6 shall apply to you if you are subject to Section 409A of the United States Internal Revenue Code
of 1986 (the “Code”), but only with respect to any payment due hereunder that is subject to Section 409A of the Code.

 

6.2
Release. The requirement to execute an irrevocable release to receive a payment hereunder shall apply to payments described
in Section 6.1 above only if the Company provides the release document for execution to you on or before the date of your Involuntary
Termination.

 

6.3
Payment Following Involuntary Termination. Notwithstanding any provision herein to the contrary, any payment described in
Section 6.1 that is due to be paid within a stated period following your Involuntary Termination shall be paid:

 

(a)
If, at the time of your Involuntary Termination, you are a “specified employee” as defined in Section 409A of the Code, such
payment shall be made as of the later of (i) the date payment is due hereunder, or (ii) the earlier of the date which is six months after
your “separation from service” (as defined under Section 409A of the Code), or the date of your death; or

 

(b)
In any case, on the later of (i) the last day of the stated period, or if such stated period is not more than 90 days, at any time during
such stated period as determined by the Company without any input from you, or (ii) the date of your “separation from service”
(as defined under Section 409A of the Code).

 

6.4
Reimbursements. The following shall apply to any reimbursement that is a payment described in Section 6.1: (a) with respect
to any such reimbursement under Section 7.8, reimbursement shall not be made unless the expense is incurred during the period beginning
on your effective hire date and ending on the sixth anniversary of your death; (b) the amount of expenses eligible for reimbursement
during your taxable year shall not affect the expenses eligible for reimbursement in any other year; and (c) the timing of all such reimbursements
shall be as provided herein, but not later than the last day of your taxable year following the taxable year in which the expense was
incurred.

 

6.5
Offset. If you are subject to Section 409A of the Code, any offset under Section 7.11 shall apply to a payment described in
Section 6.1 only if the debt or obligation was incurred in the ordinary course of your employment with the Company, the entire amount
of the set-off in any taxable year of the Company does not exceed $5,000, and the offset is made at the same time and in the same amount
as the debt or obligation otherwise would have been due and collected from you.

 

6.6
Interpretation. This Offer Letter shall be interpreted and construed to avoid the additional tax under Section 409A(a)(1)(B)
of the Code, or any like provision, to the maximum extent practicable.

 

    	11

    	 

    

 

7.
General Provisions.

 

7.1
Entire Agreement. This Offer Letter, together with the plans and documents referred to herein, constitutes and expresses the
whole agreement of the parties hereto with reference to any of the matters or things herein provided for or herein before discussed or
mentioned with reference to your employment. All promises, representations, collateral agreements, and undertakings not expressly incorporated
in this Offer Letter are hereby superseded by this Offer Letter.

 

7.2
Amendment. This Offer Letter may be amended or modified only by a writing signed by both of the parties hereto.

 

7.3
Assignment. This Offer Letter may be assigned by the Company to any successor to its business or operations. Your rights hereunder
may not be transferred by you except by will or by the laws of descent and distribution and except as far as applicable law may
otherwise require. Any assignment in violation of the preceding sentence shall be void.

 

7.4 Governing
Law; Consent to Personal Jurisdiction, Venue and Arbitration. This Offer Letter takes effect upon its acceptance by you and
execution by the Company. The validity, interpretation, and performance of this Offer Letter shall be governed, interpreted, and
construed in accordance with the laws of the State of Nevada without giving effect to the principles of comity or conflicts of laws
thereof. You hereby consent to personal jurisdiction and venue, for any action brought by the Company arising out of a breach or
threatened breach of this Offer Letter, or out of the relationship established by this Offer Letter, exclusively in the United
States District Court for the District of Nevada, Reno Division, or in the Second Judicial District, Washoe County, Nevada, or, if
applicable, the federal and state courts in any jurisdiction where you are employed or reside.

 

Except
for disputes, controversies, or claims or other actions seeking injunctive or equitable relief, which may be brought before any court
having jurisdiction, any controversy, dispute, or claim (“Claim”) whatsoever between you on the one hand, and the
Company, or any of its Affiliates or any employees, officers, directors, agents, and representatives of the Company or its Affiliates
on the other hand, shall be settled by binding arbitration, at the request of either party, under the rules of the American Arbitration
Association. The arbitrator shall apply Nevada law. The demand for arbitration must be in writing and made within the applicable statute
of limitations period. The arbitration shall take place in Reno, Nevada, or in another location mutually agreed to by the parties. The
parties shall be entitled to conduct reasonable discovery, including conducting depositions and requesting documents. The arbitrator
shall have the authority to resolve discovery disputes, including but not limited to determining what constitutes reasonable discovery.
The arbitrator shall prepare in writing and timely provide to the parties a decision and award which includes factual findings and the
reasons upon which the decision is based.

 

The
decision of the arbitrator shall be binding and conclusive on the parties, except as may otherwise be required by law. Judgment upon
the award rendered by the arbitrator may be entered in any court having proper jurisdiction. Each party shall bear its or his own fees
and costs incurred in connection with the arbitration, except that the arbitrator may award attorneys’ fees and costs in accordance
with applicable law.

 

    	12

    	 

    

 

You
understand and agree that by using arbitration to resolve any Claims between you and the Company (or its Affiliates) you are giving up
any right that you may have to a judge or jury trial regarding those Claims.

 

7.5
Severability. The invalidity of any one or more of the words, phrases, sentences, clauses, or sections contained
in this Offer Letter shall not affect the enforceability of the remaining portions of the Offer Letter or any part thereof, all of which
are inserted conditionally on their being valid in law, and, in the event that any one or more of the words, phrases, sentences, clauses,
or sections contained in the Offer Letter shall be declared invalid, the Offer Letter shall be construed as if such invalid word or words,
phrase or phrases, sentence or sentences, clause or clauses, or section or sections had not been inserted.

 

7.6
Section Headings and Gender. The section headings contained herein are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Offer Letter. All pronouns and any variations thereof shall be deemed to refer to the
masculine, feminine or neuter, as the identity of the person or persons may require.

 

7.7
No Term of Employment. Nothing herein obligates the Company to continue to employ you. Where lawfully permitted in any
jurisdiction in which you perform employment responsibilities on behalf of the Company, your employment shall be at will.

 

7.8
Indemnification. The Company will indemnify and hold you harmless to the maximum extent permitted by applicable law against
judgments, fines, amounts paid in settlement and reasonable expenses, including reasonable attorneys’ fees, in connection with
the defense of, or as a result of any action, suit, or proceeding, whether civil, criminal, administrative, or investigative (a “Proceeding”)
(or any appeal from any such Proceeding), other than any Proceeding initiated by you or the Company related to any contest or dispute
between you and the Company with respect to this Offer Letter or your employment hereunder, in which you are made or are threatened to
be made a party by reason of the fact that you are or were an director, officer, member, employee, or agent of the Company or any Affiliate.
In addition, the Company agrees that you shall be covered and insured up to the maximum limits provided by any insurance which the Company
maintains to indemnify its directors and officers (as well as any insurance that it maintains to indemnify the Company for any obligations
which it incurs because of its undertaking to indemnify its officers and directors). Costs and expenses incurred by you in defense of
a Proceeding (including attorneys’ fees) shall be paid by the Company in advance of the final disposition of such litigation upon
receipt by the Company of: (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount, and nature
of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on your
behalf to repay the amounts so paid if it shall ultimately be determined that the you are not entitled to be indemnified by the Company
under this Offer Letter.

 

7.9
Survivorship. Upon the termination of your employment, the respective rights and obligations of the parties shall survive
such termination to the extent necessary to carry out the intended preservation of such rights and obligations.

 

7.10
Taxes. All payments under this Offer Letter shall be subject to withholding of such amounts, if any, relating to tax or other
payroll deductions as the Company may determine and should withhold pursuant to any applicable law or regulation.

 

    	13

    	 

    

 

7.11
Set-Off. The Company may set off any amount or obligation which may be owed by you to the Company against any amount or obligation
owed by the Company to you.

 

7.12
Records. All books, records, and accounts relating in any manner to the Company or to any suppliers, customers, or clients
of the Company, whether prepared by you or otherwise coming into your possession, shall be the exclusive property of the Company and
immediately returned to the Company upon termination of employment or upon request at any time.

 

7.13
Return of Company Property. You agree not to remove (either physically or electronically) any property belonging to the Company
from the Company’s premises, except as required in the ordinary course of your employment, unless the Company grants you express
written authorization to do so. Upon the termination of your employment, and earlier if the Company requests at any time, you shall deliver
to the Company (and shall not keep copies in your possession or deliver to any other person or entity) all of the Company’s property
in your possession. This requirement to return the Company’s property shall also be a condition of the Company’s right to
keep an amount of money or benefit paid to you upon your termination, if any. Further, the Company has the right to pursue all legal
remedies to: (i) achieve the return of Company property; (ii) recoup any money, or value of any benefit, paid to you upon your termination;
and (iii) obtain reasonable attorneys’ fees, costs, or disbarments incurred in the exercise of its legal rights under this Section.

 

7.14
Counterparts. This Offer Letter may be executed in counterparts, each of which shall be deemed to be an original but all of
which together shall constitute the same instrument.

 

7.15
Consultation with Counsel. You acknowledge that you have conferred with your own legal counsel with respect to this Offer
Letter, and that you understand the restrictions and limitations that it imposes upon your conduct.

 

7.16
Tax Consequences. You understand and acknowledge that the execution and acceptance of this Offer Letter may create a taxable
event as it pertains to any equity compensation you may receive pursuant to the terms of this Offer Letter, as determined by applicable
securities and tax laws. You understand and acknowledge that the Company is not responsible for advising you regarding the tax or other
legal consequences pertaining to the execution and acceptance of this Offer Letter. Should you have questions regarding any such tax
consequences, the Company encourages you to consult with legal tax counsel.

 

Please
indicate your acceptance of this offer by returning one signed original of this Offer Letter.

 

    	14

    	 

    

 

Yours
truly,

 

		 	 
	Julie
    Blunden	 	Date
	Board
    Member	 	 
	American
    Battery Technology Company	 	 

 

I
accept this offer of employment and agree to be bound by the terms and conditions listed herein.

 

		 	
	Ryan
    Melsert, CEO and CTO	 	Date
	American
    Battery Technology Company	 	 

 

    	15

    	 

    

 

SCHEDULE
A

 

A.
Compensation. Pursuant to the terms of this Offer Letter, you shall be entitled to receive the following compensation:

 

1.
Annual Base Salary: $425,000 per year.

 

		●	At your request, a portion
                                                                                                                                                             of this compensation may be elected to be received as restricted stock units (RSUs) and the Annual Base Salary will be reduced to
                                                                                                                                                             $325,000 per year from the Employment Date of this Agreement through December 31, 2022 as the Company ramps up additional
                                                                                                                                                             revenue-generating operations, in exchange for 60,000 RSUs which fully vest on January 1, 2023

 

2.
Annual Bonus Compensation: Your targeted cash bonus is set at 75% of your Annual Base Salary, which you can receive based on the
achievement of certain milestones as listed in Schedule A-1.

 

3.
Bonus Equity Compensation. Subject to approval by the Board of Directors, you will be granted an award of RSUs equal to
$1,000,000 divided by the 20-day trailing volume-weighted average price prior to the grant date, and $3,000,000-worth of warrants with
a five-year expiration of a quantity and exercise price as calculated by Black-Scholes at the time of grant, which shall be conditioned
on you achieving certain performance milestones as listed in Schedule A-1. The 4-year vesting schedule for these RSUs and warrants is
defined below. The details surrounding the Bonus Equity Compensation may be memorialized by the Board in a separate award agreement,
subject to the Company 2021 Equity Retention Plan at the discretion of the Board.

 

	Continued Employment after Grant Date	 	Percent of 

Units Vested	 
	Less than One Year	 	 	0	%
	One Year	 	 	25	%
	Two Years (vested quarterly at 6.25% a quarter)	 	 	50	%
	Three Years (vested quarterly at 6.25% a quarter)	 	 	75	%
	Four Years (vested quarterly at 6.25% a quarter)	 	 	100	%

 

4.
You may be granted additional cash or equity compensation based on annual performance reviews and Company performance, subject to Board
approval.

 

5.
Benefits. You will be eligible for the Company’s healthcare, 401K, and any other employee benefits.

 

B.
Term. Two years.

 

C.
Effective Date: August 1, 2022.

 

    	16

    	 

    

 

SCHEDULE
A-1

 

Fiscal
Year 2023 Bonus Milestone Criteria

 

Bonus
Compensation Milestones

 

Weighting
of each milestone is identified below.

 

	 	1.	20%:
    Commissioning of Battery Recycling Pilot Plant: Commissioning of the battery recycling pilot plant in Fernley, NV, as quantified
    by having manufactured an initial cumulative 100 metric tons of sellable product;
	 	 	 
	 	2.	20%:
    Strategic Relationships and Sourcing of Feed Material: Formalizing strategic agreements with partners, as quantified by having
    contractually secured an additional 5,000 metric tons of feed material after the Effective Date of this agreement;
	 	 	 
	 	3.	20%:
    Additional Qualification of Recycled Battery Metal Products: Qualification of analytical samples of lithium, nickel, cobalt,
    and manganese products manufactured from recycled battery materials each meet all quality and morphology specifications, as demonstrated
    by written validation by a new external cathode manufacturer after the Effective Date of this Agreement;
	 	 	 
	 	4.	20%:
    Additional Qualification of Primary-sourced Lithium Hydroxide Product: Qualification that an analytical sample of lithium hydroxide
    product manufactured from primary sedimentary claystone feedstock meets all quality and morphology specifications, as demonstrated
    by written validation by a new external cathode manufacturer after the Effective Date of this Agreement;
	 	 	 
	 	5.	10%:
    Employee Health & Safety: Manage and enforce Company’s health and safety plan and procedures, as demonstrated by having
    zero OSHA Recordable Incidents in FY23;
	 	 	 
	 	6.	10%:
    Contractual and compliance requirements: Company will be compliant with terms of all contracts and reporting requirements demonstrated
    by maintain good standing on all government contracts, meeting all SEC rules and regulations, and achieve no identified material
    weaknesses in internal controls during the FY23 audit.

 

    	17

    	 

    

 

Exhibit
A

 

Definitions

 

“Affiliate”
shall mean, with respect to any person or entity (herein the “first party”), any other person or entity that directs
or indirectly controls, or is controlled by, or is under common control with, such first party. The term “control” as used
herein (including the terms “controlled by” and “under common control with”) means the possession, directly or
indirectly, of the power to: (i) vote 50% or more of the outstanding voting securities of such person or entity, or (ii) otherwise direct
or significantly influence the management or policies of such person or entity by contract or otherwise.

 

“Business”
shall mean the business of mining and extraction of battery metals from primary resources, the development and commercialization
of new or innovative technologies for the extraction of battery metals, and the commercialization of an internally developed integrated
process for the recycling of lithium-ion batteries for the recovery of battery metals.

 

“Cause”
shall mean your:

 

(a)
willful failure to properly carry out your duties and responsibilities or to adhere to the policies of the Company (other than any such
failure resulting from incapacity due to physical or mental illness) after written notice by the Company of the failure to do so, and
such failure remaining uncorrected following an opportunity for you to correct the failure within five (5) business days of the receipt
of such notice;

 

(b)
theft, fraud, dishonesty or misappropriation, or the gross negligence or willful misconduct, involving the property, business, or affairs
of the Company, or in the conducting of your duties, including, without limitation, any breach of the representations, warranties and
covenants contained herein;

 

(c)
arrest for any act involving dishonest conduct, theft, violence, or other act of moral turpitude;

 

(d)
breach of a fiduciary duty owed to the Company;

 

(e)
breach of any obligation, representation, or warranty under this Offer Letter;

 

(f)
refusal to follow the lawful written reasonable and good faith direction of the Board or of your superior in the line of authority;

 

(g)
conduct that could harm the Company’s reputation or goodwill or that otherwise could undermine the best interests of the Company
or Affiliates;

 

(h)
material violation of the Company’s written policies or codes of conduct, including written policies related to discrimination,
harassment, performance of illegal or unethical activities, and ethical misconduct; or

 

(i)
having been determined to have a “bad actor” disqualification as set forth in Rule 506(d) of Regulation D under the Securities
Act of 1933.

 

    	18

    	 

    

 

For
purposes of this definition, no act or failure to act on the part of the executive shall be considered “willful” unless it
is done, or omitted to be done, by the executive in bad faith or without reasonable belief that the executive’s action or omission
was in the best interests of the Company. Any act, or failure to act, based on authority given pursuant to a resolution duly adopted
by the Board or on the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by the executive
in good faith and in the best interests of the Company.

 

“Disability”
shall mean any incapacity or inability by you, including any physical or mental incapacity, disease, illness, or affliction, which
has prevented, or which will prevent you from performing the essential duties of your position for six (6) consecutive months or for
any cumulative period of 125 business days (consecutive or non-consecutive) in any two (2) year period.

 

“Good
Reason” shall mean any of the following:

 

(a)
a material diminution in your title or assignment to you of materially inconsistent duties;

 

(b)
a reduction in your then-current Annual Base Salary or target bonus opportunity as a percentage of Annual Base Salary, unless such reduction
is made applicable to all senior executives;

 

(c)
relocation of your principal place of employment to a location that is more than fifty miles away from your principal place of employment
on the Employment Date, unless such relocation is affected at your request and with your approval;

 

(d)
a material breach by the Company of any provisions of this Offer Letter, or any employment agreement to which you and the Company are
parties, after written notice by you of the breach and such failure remaining uncorrected following an opportunity for the Company to
correct such failure within ten (10) days of the receipt of such notice; or

 

(e)
the failure of the Company to obtain the assumption in writing of its obligation to perform this Offer Letter by any successor to all
or substantially all the business or assets of the Company within fifteen (15) days after a merger, consolidation, sale, or similar transaction.

 

“Initial
Noncompete Period”) means the initial
twelve (12) month period after the termination of your employment with the Company

 

“Option
Noncompete Period” means the period after the termination of your employment with the Company between the end of the Initial
Noncompete Period and any date selected by the Board of Directors that is not more than twelve (12) months after the end of the Initial
Noncompete Period.

 

“Restrictive
Covenants” shall mean each of the restrictive covenants set forth in Section 5.1 to Section 5.6 of the
Agreement.

 

“Territory”
shall mean the states, counties, and countries in which the Company and its subsidiaries conduct the Business or in which the Company
plans to conduct the Business within the following twelve (12) months.

 

    	19Document

EXHIBIT 10.41

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

FIRST AMENDMENT TO COLLABORATION AGREEMENT
This Amendment to the Collaboration Agreement (“Amendment”) is entered into as of April 20, 2022 (the “Amendment Effective Date”) by and among Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), BeiGene Switzerland GmbH, a Swiss corporation with a principal place of business at Aeschengraben 27, 4051 Basel, Switzerland (“BeiGene”), and BeiGene, Ltd., a Cayman Islands exempted company incorporated with limited liability with its registered offices c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, P.O. Box 1348, Grand Cayman KY1-1108, Cayman Islands (“BeiGene Parent”).  BeiGene and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”  This Amendment amends that certain Collaboration Agreement (the “Agreement”), entered into as of October 31, 2019, by and between Amgen and BeiGene and, solely with respect to Section 13.6 thereof, BeiGene Parent.  Capitalized terms used but not defined herein have the meanings given to them in the Agreement. 
RECITALS
WHEREAS, the Agreement contains certain terms and conditions relating to the financial responsibilities of the Parties in connection with the development and commercialization of certain Amgen proprietary Products for the treatment of oncology-related diseases and conditions; and 
WHEREAS, the Parties desire to amend the Agreement upon the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties, intending to be legally bound hereby, do agree as follows:
AGREEMENT
1.Amendment to Section 1.48 of the Agreement.  Section 1.48 of the Agreement is hereby amended and replaced in its entirety as follows:
“Section 1.48    “Costs” means both internal and external costs and expenses (including the cost of allocated FTEs at the FTE Rate and Sales Force FTEs at the Sales Force FTE Rate).  [*]”
2.New Section 1.170.  The following is hereby inserted as a new Section 1.170 of the Agreement:  
“Section 1.170    “Hainan Bo Ao” shall mean Pilot Zone in the Hainan province where Bo Ao Product may be stored and then imported into the Collaboration Territory with a patient application prior to Regulatory Approval for the Bo Ao Product in the Collaboration Territory.”
3.New Section 1.171.  The following is hereby inserted as a new Section 1.171 of the Agreement:
“Section 1.171    “Bo Ao Support Costs” means all actual and, if reasonably practicable, documented costs incurred by Amgen and/or its Affiliates and pre-approved pursuant to the Supply Agreement, if applicable, [*]”  
4.New Section 1.172.  The following is hereby inserted as a new Section 1.172 of the Agreement:
“Section 1.172    “Product Team” means, for any Product [*].”  

5.New Section 1.173.  The following is hereby inserted as a new Section 1.173 of the Agreement:
“Section 1.173    “Work Package Team” means, for any Product [*].”
6.Amendment to Section 7.1.2 of the Agreement.  The following text is hereby inserted as a new Section 7.1.2(d), Section 7.1.2(e), Section 7.1.2(f), and Section 7.1.2(g), respectively, of the Agreement: [*]
7.Amendments to Section 7.2 of the Agreement.  
a.The first paragraph of Section 7.2 (Profit Sharing) of the Agreement is hereby amended and replaced in its entirety as follows:
“Section 7.2    Profit Sharing.  
(a)    Prior to the Transition Date designated by the Joint Steering Committee (generally the second Launch Readiness Review for a Product) for an In-Line Product (the “Transition Date”) pursuant to Section 3.1.1 (Transition and Development of Products) and Section 5.1.2(b) (Initial In-Line Product Transition), [*] set forth in the definition of “Commercialization and Related Costs.”  The Joint Steering Committee has designated the Transition Date for each In-Line Product as follows:  XGEVA®, [*]; BLINCYTO®, [*]; and Kyprolis®, [*]. 
For the avoidance of doubt, [*] from Amgen to BeiGene pursuant to Section 3.1.1 (Transition and Development of Products) and Section 5.1.2(b) (Initial In-Line Product Transition).
(b)    [*] set forth in the definition of “Commercialization and Related Costs” for each Pipeline Product until [*] prior to the anticipated launch date for such Pipeline Product (such date to be designated for each Pipeline Product by the Joint Alliance Committee and subject to adjustment by the Joint Alliance Committee in the event the anticipated launch date changes) (such date, the “Initiation Date”).  
(c)    The Parties will share in Profits generated by Products in the Collaboration Scope:  (i) with respect to In-Line Products, beginning on [*] and ending upon [*] for such In-Line Product; (ii) with respect to Pipeline Products, beginning on [*] and ending upon [*] for such Pipeline Product; and (iii) for such longer period as set forth in Section 5.1 for each Retained In-Line Product and each Retained Pipeline Product (i.e., for so long as such Retained In-Line Product or Retained Pipeline Product, as applicable, is sold in the Collaboration Territory); in each case as follows:”
b.Section 7.2.3 (FTE Rate) of the Agreement is hereby amended and restated in its entirety as follows:
“Section 7.2.3.  FTE Rate.
(a)    The FTE Rate used for calculation of Costs pursuant to this Article VII (Financial Consideration) with respect to any activity will be the relevant FTE Rate for [*] in which such activity was undertaken.  
(b)    Effective as of [*], the Parties agree that the Costs (calculated using the development FTE Rate (as defined in Section 1.72(i)) or commercial FTE Rate (as defined in Section 1.72(ii)), as applicable) of FTEs performing Product Team/Work Package Team strategy activities (i.e.  Support to advise 
2

on the China specific aspects of the Global Development Plan) for Pipeline Products incurred by the Parties or their respective Affiliates: (i) prior to Regulatory Approval, in accordance with the Development Plan and Development Budget will be deemed Amgen Pipeline Product Global Development Costs and subject to Global Development Cost-Share Payments in accordance with Section 7.1.2 (Global Development Cost Share) and (ii) after Regulatory Approval (including strategy activities for new indications or label expansion after Regulatory Approval), in accordance with the Commercialization Plan and Commercialization Budget, will be deemed to be Commercialization and Related Costs and included in the collaboration profit sharing pursuant to Section 7.2 (Profit Sharing).  The Product Team and Work Package Team FTEs will be initially set, and shall in no event exceed, [*] to support the Pipeline Products.  The table below sets out the 2021 baseline budget for Product Team/Work Package Team strategy FTEs based on the Pipeline Product portfolio as of the Amendment Effective Date. [*] 
(c)    The Product Team and Work Package Team FTE allocation for Pipeline Products will be adjusted by Amgen [*] based on relevant factors, [*].”
c.The following is hereby inserted as a new Section 7.2.8 of the Agreement:
“Section 7.2.8    Hainan Bo Ao Cost-Share Matters.  Notwithstanding anything to the contrary in this Agreement, with respect to the AMG 510 (also known as sotorasib or LUMAKRAS®) Product (the “Bo Ao Product”), the Parties desire to initiate the Profit-sharing arrangement set forth in Section 7.2 prior to applicable Initiation Date, subject to the following terms and conditions: 
(a)    Commercialization and Related Costs.  Prior to the applicable Initiation Date, costs (including Costs for outside services and expenses (e.g., consultants, agency fees, etc.)) for the following activities shall be considered “Commercialization and Related Costs” for purposes of determining “Amgen Costs” or “BeiGene Costs,” as applicable: 
(i)    [*];
(ii)    Medical Affairs Activities Costs incurred in connection with Hainan Bo Ao in or for the Collaboration Territory prior to commercialization and during commercialization;
(iii)    all Costs incurred by the Parties or their respective Affiliates associated with any recalls of the Bo Ao Product in the Collaboration Scope and in or for the Collaboration Territory;
(iv)    all Costs incurred by the Parties or their respective Affiliates with respect to product liability claims for the Bo Ao Product in the Collaboration Scope in the Collaboration Territory;
(v)    all Costs incurred by the Parties or their respective Affiliates associated with any returns and withdrawals of the Bo Ao Product in the Collaboration Scope in the Collaboration Territory;
(vi)    any Third Party IP Payments to the extent not already included in Manufacturing Actual Costs; and
(viii)    all unrecovered Indirect taxes, including, for the avoidance of doubt, unrecovered VAT surcharge, incurred by either Party arising with respect to payments to be made under Section 7.2.7 (Calculation of Collaboration Profits). [*]
3

Commercialization and Related Costs for purposes of this Section 7.2.8 shall not include [*] or any Cost subject to an indemnification obligation under Article XIII.
(b)    Manufacturing Actual Costs.  The Manufacturing Actual Costs incurred with respect to the Bo Ao Product in connection with Hainan Bo Ao shall be deemed “Amgen Costs” for purposes of the calculations set forth under Section 7.2 (Profit Sharing).
(c)    Net Revenues.  Net Revenues from the sale or transfer for value of the Bo Ao Product in Hainan Bo Ao shall be considered “Net Revenues” for purpose of Section 7.2 (Profit Sharing).
(d)    Support Costs.  Bo Ao Support Costs incurred with respect to Bo Ao Product in connection with Hainan Bo Ao shall be deemed “Amgen Costs” for purposes of the calculations set forth under Section 7.2 (Profit Sharing).”
8.Amendment to Section 7.9 of the Agreement.  Section 7.9 (Overruns) of the Agreement is hereby supplemented and amended by adding the following at the end of the existing Section 7.9:
“Without limiting the foregoing, the Parties further agree as follows:
(a)    While the final overrun calculation is based on annual amounts, the Parties agree to perform quarterly assessments of cost variances for the Overrun Categories shown below, recognizing that both Parties have quarterly reporting requirements.
(b)    In any given calendar quarter, the quarterly profit share and development cost share calculations will reflect up to a maximum of [*] of the planned amounts of the “Overrun Categories” (with an exception for materiality described in Section 7.9(e) below).
(c)    To the extent costs exceed [*] of the budgeted amount in a given calendar quarter, the following shall apply:  The Parties agree that they will track variances above [*] of the planned amount into subsequent calendar quarters, to comply with the annual nature of the cost overage calculation in this Section 7.9.  [*]  If, at a later time, joint approval is obtained from each Party’s finance representative to the JAC for additional activities and related spending beyond the [*] cap, an adjustment will be made in the subsequent period.
(d)    To the extent costs are below budget in a given calendar quarter, actual variances resulting in underspend will be reimbursable in a subsequent period to the extent costs are for a pre-agreed upon activity that had a timing difference and the rationale for the variance is communicated, along with the rationale for why the activity/spend will be performed in a subsequent period.  The Parties may agree to a new activity to take the place of the activity that did not occur and the costs of such activity will be reimbursed if under the [*] expense cap, unless otherwise agreed.  Agreement will be obtained by each Party’s finance representatives to the JAC.
(e)    The Parties have agreed to a US$[*] dollar threshold for calendar quarter reconciliation of cost overruns, to eliminate the inefficient analysis of greater than [*] variance for smaller dollar amount categories.  [*]
(f)    Costs will be evaluated for overrun in the following manner: [*]
(g)    The baseline for the overrun calculation pursuant to this Section 7.9 will be the most recently approved Global Development Budget or Commercialization Budget, as applicable.”
9.New Section 7.12 of the Agreement.  The following is hereby inserted as a new Section 7.12 of the Agreement:
4

“Section 7.12    Additional Cost-Share Matters.  The Parties expect that from time-to-time one Party may perform activities that are the responsibility of the other Party or a Party may request that the other Party provide services or conduct activities that are not contemplated by the Agreement.  In these instances, if the JAC approves such activities and the budget for such activities, the Party performing the activity for the benefit of the other Party shall be reimbursed for the reasonable costs of providing such services or conducting such activities.  Such costs shall be documented in writing and the Party providing such service shall be reimbursed quarterly to the Party performing such service concurrently with the Compensating Payment made pursuant to Section 7.2.7 (Calculation of Collaboration Profits).  As of the Effective Date, the Parties have agreed that Amgen shall be reimbursed for the following activities as set forth below: [*]”
10.Supply Price Schedule.  The Supply Price Schedule is hereby amended to include the following as a new row:
						
	[*]	[*]

11.Miscellaneous.  
d.Except as specifically amended above, the Agreement shall continue to be in full force and effect.
e.This Amendment and its effect are subject to and shall be construed and enforced in accordance with the laws of the State of New York, U.S.A.
f.This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document.  All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument.  Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof.

5

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

AMGEN INC.

			
	/s/ Rachna Khosla

Name: Rachna Khosla
Title: SVP Business Development

BEIGENE SWITZERLAND GMBH

			
	/s/ Beatriz Martinez-Lahuerta

Name: Beatriz Martinez-Lahuerta
Title: Assistant General Counsel, Head of Legal, Europe & New Markets

BEIGENE, LTD.

			
	/s/ Angus Grant

Name: Angus Grant
Title: Senior Vice President, Chief Business Executive

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]